BioMimetic Therapeutics Inc.

Samuel E. Lynch, D.M.D., D.M.Sc. is founder, President, Chief Executive Officer of BioMimetic. Dr. Lynch also served as Chairman of our board of directors from company inception in 1999 until August 2005. He has spent his career in health care management, product development, and earlier in academic medicine/dentistry, including research and patient care. He received his Doctorate of Medical Sciences and Specialty in Periodontology from the Harvard Medical and Dental Schools respectively as well as a Doctorate of Dental Medicine from Southern Illinois University School of Dental Medicine. He has published and lectured extensively worldwide and is a co-inventor of BioMimetic's technologies. In this era of complex regulatory environments he is one of only a handful of doctors to have been fortunate enough to make a breakthrough discovery and oversee its development through all phases of product development culminating in FDA approval and commercialization. Dr. Lynch is also a member of the board of directors of GreenBankshares, Inc. and numerous non-profit organizations.

Larry Bullock joined BioMimetic in January 2004 as Chief Financial Officer. From January 1996 to February 2003, Mr. Bullock served as Chief Financial Officer of Ribozyme Pharmaceuticals Inc., now called Sirna Pharmaceuticals Inc., and as Chief Financial Officer of La Jolla Pharmaceuticals for five years prior to joining Sirna. He led both companies through their private to public transitions, completing private and initial public offerings and building the public reporting team. Mr. Bullock received his M.B.A. from the University of Utah and his B.A. from Indiana University.

Steve Hirsch joined BioMimetic in July 2005 as Executive Vice President, Orthopedics and Chief Operating Officer. From October 1996 to June 2005, Mr. Hirsch served in various positions in the Orthopedics Division of London-based Smith & Nephew, plc. His responsibilities at Smith & Nephew included responsibilities in the marketing and sales areas. From January 2003 to February 2005, Mr. Hirsch was the Senior Vice President and General Manager of the Reconstructive (total joint) Division of the orthopedics business. His last position with Smith & Nephew was President of the European Orthopedic business, with annual revenues in excess of $200 million. Mr. Hirsch spent 24 years in the orthopedic device industry, first with the Howmedica Division of Pfizer, Inc. where he held a variety of positions including Vice President of Sales and Marketing for the US Orthopedics business. Mr. Hirsch received a B.E.Sc. from the Johns Hopkins University and a M.S.I.A. from the Krannert School of Business at Purdue University.

Thorkil K. Christensen , age 61, currently serves as the Chief Financial Officer of Novo A/S, where he has served in that position since 2003. From 1989 to 2003, he served in various positions at Novo Nordisk A/S, including Managing Director of Health Care Asia, Vice President of International Operations and Chief Executive Officer of China Operations. Mr. Christensen also currently serves on the boards of Nordic Institute of Asian Studies and Executives Global Network A/S, and as Vice Chairman of the Danish Chinese Business Forum.

Thorkil K. Christensen , age 61, currently serves as the Chief Financial Officer of Novo A/S, where he has served in that position since 2003. From 1989 to 2003, he served in various positions at Novo Nordisk A/S, including Managing Director of Health Care Asia, Vice President of International Operations and Chief Executive Officer of China Operations. Mr. Christensen also currently serves on the boards of Nordic Institute of Asian Studies and Executives Global Network A/S, and as Vice Chairman of the Danish Chinese Business Forum.

Leo Snel joined BioMimetic in August 2007 and is Senior Vice President of R&D Protein Biochemistry. He brings 30 years of protein science and product development expertise to BMTI, most recently at Amgen leading a Global Operations team to launch Amgen's first oncology protein therapeutic, Vectibix. Mr. Snel also led the CMC section filing of the BLA (Biologics License Application) and PLA (Production Facility License Application) for Vectibix, an antibody to treat late stage colorectal cancer. Prior to that, Mr. Snel spent two years at ZymoGenetics as Senior Director of Analytical Sciences and Contract Manufacturing, and 24 years at NovoNordisk where he held a variety of positions, including 6 years as Director of Biologics Development for the Health Care Division and was involved in regulatory filings worldwide involving recombinant insulins, liquid formulation of growth hormones (hGH Simplexx) and blood factor VII (NovoSevenn). He received his MSc from the Technical University of Denmark and a Diploma in Drug & Device Development from the Scandinavian International Management Institute.

Hans Kestler joined BioMimetic in 2006 and is vice president, sports medicine. Previously, Mr. Kestler was director of orofacial healthcare and was responsible for both product and business development in support of the Company's first approved product, GEM 21S. Since successfully leading the divestiture of the Orofacial business to Luitpold Pharmaceuticals in early 2008, Mr. Kestler leads a focused team of research scientists pursuing the use of rhPDGF-BB in cartilage, tendon and ligament applications. Mr. Kestler's prior management experience includes leadership responsibilities in marketing, sales and product development in several medical device/tissue engineering therapeutic areas.

James Monsor is Vice President, Operations. Mr. Monsor spent 15 years in positions of increasing responsibility at Abbott Laboratories within operations and quality. Most recently, he was Director of Product Supply for ALK-Abello, where he was responsible for the entire product supply chain for US operations. He has had responsibility for all aspects of supply chain management, quality assurance, quality control, regulatory affairs, customer service, facilities management, construction management, and HR. His experience includes Aseptic Processing, Medical Devices, and Bulk Pharmaceuticals.

John McKay joined the Company effective September 28, 2007 and holds the position of Vice President, Quality and Environmental, Health, Safety (EHS). Mr. McKay brings 22+ years of international experience in the fields of Quality, EHS, Operations, Engineering, Compliance, Training, Integrated Auditing, Maintenance/Reliability and Product Development programs to BMTI. Most recently he served as Senior Director, Compliance at Stryker Physiotherapy Associates where he led the systems for healthcare quality, compliance and Corporate Integrity Agreement, and assured compliance with regulatory, ethics, code of conduct and company policies. Prior to that, he held several senior management positions within the Bayer Corporation, including Manager, Operational Excellence, leading global efforts for performance improvement, ISO standards, quality, management systems, and integrated auditing. He also spent 15 years at Lyondell, ARCO Chemical Company, Rohm and Haas Company where he held various global management positions in Manufacturing Excellence, Operational Excellence, Quality Assurance, Quality Control, EHS, Operations, Product Development, Engineering, Training, Supply Chain Management, Plant Management, Maintenance/Reliability, and Integrated Auditing. Mr. McKay received his B.S. in Chemical Engineering from Pennsylvania State University and is a graduate of the University of Pennsylvania Business School's Wharton Management Program. Mr. McKay holds several Quality, Environmental and Safety/Health certifications. His experience includes Pharmaceuticals, Medical Devices, Specialty/Intermediate Chemicals, Petrochemicals, and Contract Manufacturing.

Russ Pagano, Ph.D. joined the Company effective May 23, 2007 in the position of vice president of regulatory and clinical affairs. Dr. Pagano received his Ph.D. from Duke University and joined the US Food and Drug Administration ("FDA") as a scientific reviewer in the Office of Device Evaluation in 1994. He served as FDA chief of the Restorative Devices Branch, which included a portion of the organization's orthopedic products from 1997 to 2000. While leading this branch, he reviewed bone void fillers (BVF)and bone morphogenic protein (BMP)products from companies such as Medtronic and Stryker. He also held the position of FDA chief of the Pacing, Defibrillators and Leads Branch from October 2000 to May 2001. Since that time, he has been executive vice president and regulatory advisor at M Squared Associates, a consulting firm in Washington D.C. In that capacity, Dr. Pagano served as a regulatory consultant to BioMimetic and numerous other companies and helped prepare PMAs for filing and provided panel preparation services.

William Beasley is Vice President, Clinical Research. He previously served five years in clinical trials management at Covance, Inc., a large, multinational Clinical Research Organization (CRO) where he directed phase I - phase III clinical trials for major international pharmaceutical companies. In his current position, Mr. Beasley successfully conducted the pivotal trial on GEM 21S and has lead the Company's ongoing orthopedic clinical research program. He has implemented an electronic data capture (EDC) instrument developed by a small CRO into the company's clinical program, substantially improving clinical trial efficiencies. Mr. Beasley's clinical research management experience includes a diverse range of pharmaceuticals, biologics, medical devices and combination products in multiple therapy areas.

Mr. Federico joined the BioMimetic board of directors in June of 2007. Mr. Federico currently serves as a director of Orthofix International N.V., where he also served as president from 1996 to 2001, and as president and chief executive officer from 2001 to 2006. From 1985 to 1996, Mr. Federico was general manager then president of Smith & Nephew Endoscopy (formerly Dyonics, Inc.). From 1981 to 1985, Mr. Federico served as vice president of Dyonics, initially as director of marketing and subsequently as general manager. Previously, he held management and marketing positions with General Foods Corporation, Air Products Corporation, Puritan Bennett Corporation and LSE Corporation. Mr. Federico also currently serves on the boards of SRI/Surgical Express, Inc., SaluMedica, LLC and Mako Surgical Corp.

Douglas Watson has been a director since 1999. Mr. Watson s career spanned 33 years with Geigy/Ciba-Geigy/Novartis, in a variety of positions, including President of Ciba Pharmaceuticals Division from April 1986 to March 1996, President and Chief Executive Officer of Ciba-Geigy Corporation from April to December 1996, and President and Chief Executive Officer of Novartis Corporation, the U.S. subsidiary of Novartis AG, from January 1997 to May 1999. In 1999, Mr. Watson founded Pittencrieff Glen Associates, a private management consulting company. In addition to BioMimetic, he has served as the chairman of OraSure Technologies Inc. since March 2003 and as a director since April 2002. He has served as the chairman of Javelin Pharmaceuticals, Inc. since June 2003 and as a director since March 2001. He has served as a director of Dendreon Corporation since March 2000 and Genta Inc. since April 2002. Mr. Watson holds an M.A. degree in pure mathematics from Churchill College, Cambridge University, and is a member of the Chartered Institute of Management Accountants.

Jim Murphy has been a director since September 2005. Mr. Murphy recently joined NMS Labs as Vice President, Finance. Prior to NMS, he served as Senior Vice President, Finance and Administration, and as Chief Financial Officer, of Immunicon Corporation since September 2000. From April 1999 to September 2000, Mr. Murphy served as Immunicon's Vice President, Finance and Administration. From April 1998 to April 1999, he was a consultant providing financial services to various venture-backed health care companies. From March 1996 to April 1998, Mr. Murphy was Vice President, Finance and Administration, and Chief Financial Officer of Apollon, Inc., a biotechnology company engaged in the development of DNA-based vaccines. From 1988 to 1995 Mr. Murphy served as Vice President, Chief Financial Officer and as a director of Infopage, Inc., a publicly-held radio beeper company that operated throughout the US. From 1987 to 1988, Mr. Murphy was Corporate Controller and Treasurer of American Cellular Network Corporation, a publicly-traded company that operated cellular telephone systems in New Jersey and Delaware. He holds a B.S. in Accounting, cum laude, from Villanova University, and is a certified public accountant.

Jim Murphy has been a director since September 2005. Mr. Murphy recently joined NMS Labs as Vice President, Finance. Prior to NMS, he served as Senior Vice President, Finance and Administration, and as Chief Financial Officer, of Immunicon Corporation since September 2000. From April 1999 to September 2000, Mr. Murphy served as Immunicon's Vice President, Finance and Administration. From April 1998 to April 1999, he was a consultant providing financial services to various venture-backed health care companies. From March 1996 to April 1998, Mr. Murphy was Vice President, Finance and Administration, and Chief Financial Officer of Apollon, Inc., a biotechnology company engaged in the development of DNA-based vaccines. From 1988 to 1995 Mr. Murphy served as Vice President, Chief Financial Officer and as a director of Infopage, Inc., a publicly-held radio beeper company that operated throughout the US. From 1987 to 1988, Mr. Murphy was Corporate Controller and Treasurer of American Cellular Network Corporation, a publicly-traded company that operated cellular telephone systems in New Jersey and Delaware. He holds a B.S. in Accounting, cum laude, from Villanova University, and is a certified public accountant.

Larry W. Papasan is the retired President of the Orthopaedic Division in Memphis, TN for Smith and Nephew. He serves on various boards, including Plough Foundation, University of Memphis Board of Visitors, and the LeBonheur Foundation.

Earl Douglas, Esq. joined BioMimetic in May 2005 as General Counsel. Mr. Douglas has been a practicing attorney for almost 20 years and has a strong background in intellectual property law. Mr. Douglas served as Vice President and General Counsel of Spinal Dynamics Corporation from December 2001 to December 2002 and as Chief Patent Counsel from October 2000 to December 2001. Mr. Douglas was an intellectual property attorney for Smith & Nephew, Inc. from July 1995 to October 2000. Mr. Douglas received his J.D. from Columbia University and his B.S. in chemical engineering from the Massachusetts Institute of Technology.

Dr. Gary Friedlaender has been a director of BioMimetic's board of directors since September 2006. Dr. Friedlaender is Chief of the Department of Orthopaedics and Rehabilitation at Yale New Haven Hospital and Professor of Orthopaedics and Rehabilitation at the Yale University School of Medicine. After earning his medical degree at the University of Michigan Medical School in Ann Arbor, Dr. Friedlaender completed his general surgery internship and residency at the University of Michigan Medical Center, and his orthopaedic residency at the Yale – New Haven Hospital and Newington Children's Hospital in Newington, Conn. He then completed a fellowship in musculoskeletal oncology at Massachusetts General Hospital in Boston. During active duty in the U.S. Navy, he was Director of the Naval Medical Research Institute's Tissue Bank Division in Bethesda, Md., and has since served on various medical advisory committees for the National Institutes of Health. Dr. Friedlaender has received several research grants and written numerous articles related to orthopedic reconstruction and bone grafting.

Douglas G. Watson is the founder of Pittencrieff Glen Associates, which was established in June, 1999. Prior to this, he was President and Chief Executive Officer of Novartis Corporation, the US subsidiary of Novartis A.G. Mr. Watson's career spanned 33 years with Geigy / Ciba-Geigy / Novartis. He joined Geigy (UK) Ltd in 1966, working first in Operations Research and then in Corporate Planning. Following the Ciba-Geigy merger, he spent one year in Basel , Switzerland as the UK representative to an international integration team. He returned to the UK in 1973 as accounting development and investment appraisal manager, and subsequently headquarters management accountant. In 1978, Doug returned to Basel as personal assistant to the Chairman of the Executive Committee. In 1981, he joined the US Pharmaceuticals Division as senior vice president of planning and business development, and a member of the Pharmaceuticals Management Committee. From 1986, he was President of Ciba Pharmaceuticals Division until 1996, when he was appointed President & CEO of Ciba-Geigy Corporation. During this ten year period, Mr. Watson was an active member of the Pharmaceutical Research & Manufacturers Association (PhRMA) board in Washington , DC . Mr. Watson became President & CEO of Novartis Corporation in 1997 when Ciba-Geigy & Sandoz merged. Mr Watson elected to take early retirement from Novartis in May, 1999. Mr. Watson, in addition, is Chairman of the board of OraSure Technologies Inc., and serves as a member of the board of directors for Engelhard Corporation, Genta Inc., Dendreon Corporation, BZL Biologics Inc., BioMimetic Pharmaceuticals Inc., BioElectronics Inc., InforMedix, Inc., and Innovative Drug Delivery Systems Inc. Prior board memberships include Novartis Corporation, Summit Bank Corporation, Principia Pharmaceuticals Inc., and ValiGen N.V. He has been a supporter of America 's Promise since its inception, and is chairman of the Freedom House Foundation, a non-profit organisation which treats adult men & women recovering from alcohol and drug addiction. He is a member of the Board of Directors of the American Liver Foundation, and on the President's Advisory Council of Drew University . Born near Pittencrieff Glen in the city of Dunfermline, Scotland, Mr. Watson holds an MA degree in pure mathematics from Churchill College, Cambridge University, and is a member of the Chartered Institute of Management Accountants.